ZTS

ZTS

USD

Zoetis Inc. Class A Common Stock

$119.830-0.600 (-0.498%)

Real-time Price

Healthcare
Drug Manufacturers - Specialty & Generic
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$120.430

High

$121.310

Low

$118.520

Volume

8.35M

Company Fundamentals

Market Cap

52.8B

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

Trading Stats

Avg Volume

3.12M

Exchange

NYQ

Currency

USD

52-Week Range

Low $117.26Current $119.830High $181.85

Related News

Analyst Upgrades

Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175

Morgan Stanley analyst Erin Wright maintains Zoetis with a Overweight and lowers the price target from $211 to $175.

View more
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175
Analyst Upgrades

Zoetis Stock Outlook Clouded By Rising Competitive Pressures

Zoetis tops Q3 earnings estimates but trims 2025 sales forecast as companion animal growth slows and competition weighs on its outlook.

View more
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
BusinessWire

Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career

View more
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
BusinessWire

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing

View more
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
BusinessWire

Zoetis Appoints Stephanie Tilenius to its Board of Directors

Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as

View more
Zoetis Appoints Stephanie Tilenius to its Board of Directors